Logo image of TRAW

TRAWS PHARMA INC (TRAW) Stock Fundamental Analysis

NASDAQ:TRAW - US68232V8845 - Common Stock

1.48 USD
+0.04 (+2.78%)
Last: 9/3/2025, 10:56:44 AM
Fundamental Rating

4

TRAW gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. While TRAW seems to be doing ok healthwise, there are quite some concerns on its profitability. TRAW is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

TRAW had positive earnings in the past year.
TRAW had a negative operating cash flow in the past year.
TRAW had negative earnings in each of the past 5 years.
TRAW had a negative operating cash flow in each of the past 5 years.
TRAW Yearly Net Income VS EBIT VS OCF VS FCFTRAW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

TRAW's Return On Assets of 562.73% is amongst the best of the industry. TRAW outperforms 100.00% of its industry peers.
TRAW has a Return On Equity of 1064.03%. This is amongst the best in the industry. TRAW outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 562.73%
ROE 1064.03%
ROIC N/A
ROA(3y)-116.91%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRAW Yearly ROA, ROE, ROICTRAW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

TRAW's Profit Margin of 3028.25% is amongst the best of the industry. TRAW outperforms 100.00% of its industry peers.
The Operating Margin and Gross Margin are not available for TRAW so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 3028.25%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRAW Yearly Profit, Operating, Gross MarginsTRAW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

6

2. Health

2.1 Basic Checks

TRAW does not have a ROIC to compare to the WACC, probably because it is not profitable.
TRAW has more shares outstanding than it did 1 year ago.
TRAW has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TRAW Yearly Shares OutstandingTRAW Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 1M 2M 3M
TRAW Yearly Total Debt VS Total AssetsTRAW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

TRAW has an Altman-Z score of -58.98. This is a bad value and indicates that TRAW is not financially healthy and even has some risk of bankruptcy.
TRAW has a Altman-Z score of -58.98. This is amonst the worse of the industry: TRAW underperforms 91.79% of its industry peers.
There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -58.98
ROIC/WACCN/A
WACC10.09%
TRAW Yearly LT Debt VS Equity VS FCFTRAW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 2.09 indicates that TRAW has no problem at all paying its short term obligations.
TRAW's Current ratio of 2.09 is on the low side compared to the rest of the industry. TRAW is outperformed by 60.00% of its industry peers.
TRAW has a Quick Ratio of 2.09. This indicates that TRAW is financially healthy and has no problem in meeting its short term obligations.
TRAW's Quick ratio of 2.09 is in line compared to the rest of the industry. TRAW outperforms 45.64% of its industry peers.
Industry RankSector Rank
Current Ratio 2.09
Quick Ratio 2.09
TRAW Yearly Current Assets VS Current LiabilitesTRAW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 114.90% over the past year.
Looking at the last year, TRAW shows a very strong growth in Revenue. The Revenue has grown by 1184.51%.
EPS 1Y (TTM)114.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.91%
Revenue 1Y (TTM)1184.51%
Revenue growth 3Y0%
Revenue growth 5YN/A
Sales Q2Q%4694.74%

3.2 Future

Based on estimates for the next years, TRAW will show a very strong growth in Earnings Per Share. The EPS will grow by 41.24% on average per year.
The Revenue is expected to grow by 14.21% on average over the next years. This is quite good.
EPS Next Y76.99%
EPS Next 2Y41.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y14.21%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TRAW Yearly Revenue VS EstimatesTRAW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
TRAW Yearly EPS VS EstimatesTRAW Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50K -100K -150K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 0.07, the valuation of TRAW can be described as very cheap.
Based on the Price/Earnings ratio, TRAW is valued cheaper than 99.49% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.90, TRAW is valued rather cheaply.
TRAW is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.07
Fwd PE N/A
TRAW Price Earnings VS Forward Price EarningsTRAW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRAW Per share dataTRAW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

TRAW's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TRAW's earnings are expected to grow with 41.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y41.24%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRAW!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRAWS PHARMA INC

NASDAQ:TRAW (9/3/2025, 10:56:44 AM)

1.48

+0.04 (+2.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13
Earnings (Next)11-12 2025-11-12
Inst Owners12.76%
Inst Owner Change-27.06%
Ins Owners7.76%
Ins Owner Change-28.59%
Market Cap10.45M
Analysts82.86
Price Target153 (10237.84%)
Short Float %3.01%
Short Ratio1.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2179.41%
Min Revenue beat(2)-6.86%
Max Revenue beat(2)4365.69%
Revenue beat(4)1
Avg Revenue beat(4)1088.3%
Min Revenue beat(4)-6.86%
Max Revenue beat(4)4365.69%
Revenue beat(8)1
Avg Revenue beat(8)537.82%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.07
Fwd PE N/A
P/S 3.6
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)19.77
EY1335.81%
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-3.81
FCFYN/A
OCF(TTM)-3.81
OCFYN/A
SpS0.41
BVpS1.17
TBVpS1.17
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 562.73%
ROE 1064.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 3028.25%
GM N/A
FCFM N/A
ROA(3y)-116.91%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.09
Quick Ratio 2.09
Altman-Z -58.98
F-Score6
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)114.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.91%
EPS Next Y76.99%
EPS Next 2Y41.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1184.51%
Revenue growth 3Y0%
Revenue growth 5YN/A
Sales Q2Q%4694.74%
Revenue Next Year0%
Revenue Next 2Y14.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-66.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.14%
OCF growth 3YN/A
OCF growth 5YN/A